Recently, in 2021, the addition of a checkpoint inhibitor (the PD-1 antibody nivolumab) was added in HER2 negative patients harboring a PDL1 CPS score > 5 on tumor samples in first-line gastric cancer in combination with platinum-based doublet chemotherapy [4]. Here, ERBB2 is linked to gastric cancer.